Vestibular Migraine in Neurology Clinics: The Great Mimicker Behind Recurrent Vertigo

Introduction

Vestibular migraine is one of the most common causes of recurrent episodic vertigo encountered in clinical practice and is increasingly recognized across multiple medical specialties, including neurology, otolaryngology, emergency medicine, internal medicine, and primary care. Despite its high prevalence, it remains one of the most challenging vestibular disorders to diagnose because of its heterogeneous clinical presentation, absence of a definitive diagnostic biomarker, and substantial overlap with numerous peripheral and central causes of dizziness. Patients may present with spontaneous vertigo, positional dizziness, motion sensitivity, imbalance, visual dependence, head motion intolerance, or nonspecific disequilibrium, often accompanied by migraine features that may be subtle, delayed, or entirely absent during some attacks. This broad spectrum of manifestations frequently complicates clinical assessment and contributes to both underdiagnosis and misdiagnosis.

The diagnostic challenge is compounded by the fact that vestibular migraine shares clinical features with several common vestibular disorders. Patients are frequently misdiagnosed with benign paroxysmal positional vertigo because both conditions may present with recurrent positional vertigo. However, vestibular migraine typically produces positional dizziness that is more prolonged, less stereotyped, and not consistently associated with the characteristic canal specific positional nystagmus observed in benign paroxysmal positional vertigo. Similarly, overlap with Ménière disease is common, particularly in patients experiencing episodic vertigo accompanied by tinnitus, aural fullness, or fluctuating auditory symptoms. Unlike Ménière disease, however, vestibular migraine generally lacks progressive low frequency sensorineural hearing loss, although transient auditory complaints may occur during attacks.

Recurrent vestibular neuritis also enters the differential diagnosis, especially in patients who experience repeated episodes of prolonged vertigo. True vestibular neuritis is typically a monophasic disorder characterized by acute unilateral vestibular dysfunction without hearing loss, whereas recurrent episodes should prompt consideration of alternative diagnoses such as vestibular migraine or central vestibular disorders. In addition, anxiety disorders, persistent postural perceptual dizziness, panic attacks, and autonomic dysfunction frequently coexist with vestibular migraine or mimic its presentation, further complicating diagnostic evaluation. Medication related dizziness, orthostatic hypotension, cardiac arrhythmias, and metabolic disturbances should likewise remain important considerations, particularly in older adults and patients with multiple comorbidities.

The diagnostic uncertainty also extends in the opposite direction. While vestibular migraine is commonly overlooked, there is an increasing tendency to attribute unexplained vertigo to migraine once routine investigations fail to identify an alternative cause. This approach carries significant clinical risk. A history of migraine, normal neuroimaging, or nonspecific vestibular testing should not be considered sufficient evidence for the diagnosis. Likewise, vestibular migraine should not become a default explanation simply because structural imaging is unrevealing or laboratory investigations are unremarkable. Overdiagnosis may delay recognition of serious neurological, vascular, or otological disorders requiring urgent intervention.

A systematic differential diagnosis remains essential for every patient presenting with episodic vertigo or dizziness. Careful evaluation should identify clinical features suggestive of alternative diagnoses, including reproducible positional nystagmus characteristic of benign paroxysmal positional vertigo, progressive unilateral hearing loss consistent with Ménière disease or vestibular schwannoma, persistent spontaneous nystagmus indicating acute vestibular syndromes, central ocular motor abnormalities such as direction changing gaze evoked nystagmus or impaired smooth pursuit, severe truncal or gait ataxia, cranial nerve deficits, focal neurological signs, and symptoms suggestive of posterior circulation ischemia. Particular attention should be given to patients with significant vascular risk factors, sudden onset of symptoms, severe headache of unusual character, altered consciousness, or persistent neurological deficits, as these findings may indicate cerebellar infarction or other central nervous system pathology requiring immediate evaluation.

The diagnosis of vestibular migraine is fundamentally clinical and should be based on established diagnostic criteria rather than exclusion alone. Current international criteria emphasize recurrent vestibular symptoms of moderate or severe intensity occurring in individuals with a current or previous history of migraine, with at least half of episodes associated with migraine features such as unilateral pulsating headache, photophobia, phonophobia, or visual aura. Equally important is the exclusion of other vestibular or neurological disorders that more adequately explain the patient’s symptoms. Because symptom patterns may evolve over time, longitudinal assessment and careful documentation of attack characteristics often improve diagnostic confidence.

Comprehensive history taking remains the cornerstone of evaluation. Clinicians should characterize the timing, duration, frequency, and triggers of vertigo episodes while identifying associated symptoms including headache, visual aura, nausea, vomiting, auditory complaints, motion sensitivity, and imbalance. A thorough neurological and vestibular examination should assess ocular alignment, spontaneous and gaze evoked nystagmus, smooth pursuit, saccadic eye movements, vestibulo ocular reflex function, cerebellar coordination, gait, and balance. Additional investigations such as audiometry, vestibular function testing, and magnetic resonance imaging should be guided by clinical findings rather than used indiscriminately.

The description of vestibular migraine as the “great mimicker” is clinically valuable only when it reinforces the importance of maintaining a disciplined and methodical diagnostic approach. The diagnosis should emerge from recognition of a characteristic clinical syndrome supported by accepted diagnostic criteria rather than from the absence of alternative findings. Treating vestibular migraine as a residual diagnosis for otherwise unexplained dizziness risks overlooking potentially serious disorders while exposing patients to unnecessary treatments.

Ultimately, accurate diagnosis requires integration of detailed clinical history, targeted neurological and vestibular examination, appropriate use of diagnostic testing, and careful consideration of competing diagnoses. Recognizing the diverse manifestations of vestibular migraine while avoiding premature diagnostic closure enables clinicians to provide timely, evidence based management and improves outcomes for patients presenting with recurrent dizziness and vertigo.

Why Vestibular Migraine Matters

A population-based analysis of the 2008 National Health Interview Survey estimated that 2.7% of U.S. adults met a survey-based case definition for vestibular migraine. That estimate should not be interpreted as a definitive population prevalence because it depended on retrospective survey responses and an operational case definition rather than prospective specialist diagnosis. Prevalence estimates vary considerably by diagnostic criteria, age, referral setting, and study design.

Vestibular migraine is nevertheless clinically important because attacks can impair mobility, driving, visual tolerance, work, and daily function. Some patients also experience persistent motion sensitivity, visually induced dizziness, or other interictal symptoms between discrete attacks. Current consensus criteria still define vestibular migraine as an episodic disorder. A 2026 narrative review proposed preliminary operational criteria for a chronic vestibular migraine phenotype, but these have not been adopted as formal consensus diagnostic criteria.

The therapeutic landscape has also changed. CGRP-targeting therapies are established options for migraine prevention generally, and a small randomized trial has evaluated galcanezumab specifically in vestibular migraine. Newer systematic reviews have identified favorable signals for several preventive strategies. However, the vestibular migraine evidence base remains less mature than the evidence supporting treatment of migraine headache.

Diagnostic Criteria and Important Nuances

The Bárány Society and International Headache Society criteria require all of the following for definite vestibular migraine:

1. At least five episodes with qualifying vestibular symptoms.
2. A current or previous history of migraine with or without aura.
3. Moderate or severe vestibular symptoms lasting 5 minutes to 72 hours.
4. At least half of vestibular episodes accompanied by migraine-type headache, photophobia and phonophobia, or visual aura.
5. Symptoms not better accounted for by another headache or vestibular disorder.

Qualifying symptoms include spontaneous vertigo, positional vertigo, visually induced vertigo, head motion-induced vertigo, and head motion-induced dizziness accompanied by nausea. Other nonspecific forms of dizziness are not automatically qualifying vestibular symptoms.

Headache is not required during every episode

Vertigo or motion intolerance may be the dominant complaint. Photophobia and phonophobia, visual aura, or a migraine-type headache can provide the required temporal association. Different migraine features may accompany different vestibular episodes.

The presence of migraine symptoms during vertigo does not, by itself, prove that migraine caused the vestibular syndrome. Vestibular stimulation can provoke migraine symptoms, and patients can have a peripheral vestibular disorder with superimposed migraine features.

Vestibular migraine is not migraine with brainstem aura

Fewer than 10% of patients with vestibular migraine meet criteria for migraine with brainstem aura. Vestibular migraine episodes also do not generally satisfy the timing requirements for a migraine aura. The diagnoses are therefore not interchangeable, although an individual patient may meet criteria for both.

Episode duration requires context

The core episode usually lasts 5 minutes to 72 hours. However, approximately 10% of patients described in the diagnostic framework have attacks lasting seconds that recur repeatedly with head motion, visual stimulation, or positional change. In these patients, duration refers to the total period during which the brief attacks recur.

Seconds-long, position-triggered symptoms should still prompt positional testing for BPPV. Vestibular migraine can also cause recurrent positional symptoms, so the overall pattern and observed nystagmus should guide differentiation rather than duration alone.

Auditory symptoms do not automatically exclude vestibular migraine

Transient tinnitus, aural pressure, or hearing fluctuation may occur with vestibular migraine. Progressive or audiometrically documented unilateral low- to mid-frequency sensorineural hearing loss should prompt careful assessment for Ménière’s disease.

The AAO-HNS guideline defines definite Ménière’s disease by at least two spontaneous vertigo episodes lasting 20 minutes to 12 hours, audiometrically documented low- to mid-frequency sensorineural hearing loss in the affected ear, fluctuating aural symptoms, and no better alternative diagnosis. Early differentiation can be difficult because Ménière’s disease may initially present with vestibular symptoms before a characteristic hearing pattern becomes established.

Table 1. Diagnostic Anchors and Common Mimics

Diagnosis	Typical pattern and supporting findings	Key caution
Vestibular migraine	At least five moderate or severe vestibular episodes, usually 5 minutes to 72 hours; migraine history; qualifying migraine features during at least half of episodes	Requires a positive pattern and no better vestibular or headache explanation
BPPV	Brief position-triggered vertigo with characteristic positional nystagmus on Dix-Hallpike or supine roll testing	Vestibular migraine can also produce positional symptoms; classic BPPV should receive canalith repositioning rather than migraine treatment alone
Ménière’s disease	Spontaneous vertigo lasting 20 minutes to 12 hours, fluctuating aural symptoms, and audiometric low- to mid-frequency sensorineural hearing loss	Migraine features can occur during Ménière attacks; documented hearing loss materially changes the diagnosis and workup
Posterior circulation TIA or stroke	Acute continuous vertigo or episodic vascular symptoms with central ocular motor findings, severe gait ataxia, focal deficits, or relevant vascular risk	Absence of obvious focal weakness does not exclude posterior circulation ischemia
Vestibular neuritis	Acute continuous vertigo lasting days, spontaneous nystagmus, nausea, gait instability, and no acute hearing loss	Early posterior circulation stroke can mimic neuritis
PPPD	Dizziness, unsteadiness, or nonspinning vertigo on most days for at least 3 months, worsened by upright posture, motion, or complex visual environments	May be precipitated by or coexist with vestibular migraine

The BPPV guideline supports diagnosis with characteristic positional nystagmus and treatment with a canalith-repositioning procedure. The PPPD consensus criteria require persistent symptoms on most days for at least 3 months with characteristic postural, motion, and visual exacerbation.

Clinical Phenotype

Vestibular migraine is more accurately viewed as a migraine-spectrum disorder involving vestibular and multisensory processing than as simply “vertigo plus headache.” Reviews and physiologic studies have described altered visual-motion processing, sensory integration, vestibular-thalamocortical interactions, and possible involvement of CGRP pathways. These findings support biologic plausibility but do not establish one proven mechanism that explains every clinical phenotype.

The history is often more informative than any single test. Patients may describe spinning vertigo, rocking, tilting, visually induced dizziness in stores or crowds, intolerance while scrolling screens, head-motion sensitivity, nausea, photophobia, phonophobia, osmophobia, migraine headache, or post-attack exhaustion. Some attacks occur without headache, while others begin with vestibular symptoms and later develop migraine features.

This phenotypic variability contributes to overlap with BPPV, Ménière’s disease, recurrent peripheral vestibular syndromes, anxiety-related dizziness, medication effects, cervicogenic symptoms, PPPD, and posterior circulation ischemia. A normal MRI or nonspecific vestibular test does not confirm vestibular migraine. The condition remains a clinical diagnosis based on affirmative criteria.

Practical Diagnostic Approach

A practical evaluation begins with timing and triggers. The clinician should determine whether the patient has:

• Acute continuous dizziness or vertigo
• Spontaneous episodic vertigo
• Triggered episodic vertigo
• Chronic persistent dizziness

GRACE-3 supports this timing-and-triggers framework for adults presenting to an emergency department with acute dizziness or vertigo of less than 2 weeks’ duration. The same categories can organize an ambulatory history, but the guideline’s bedside-examination and imaging recommendations should be applied only within the acute syndromic contexts for which they were developed.

For recurrent spontaneous episodes, the history should document episode duration, frequency, vestibular phenotype, migraine history, accompanying photophobia or phonophobia, visual aura, headache timing, hormonal associations, sleep disruption, alcohol exposure, suspected triggers, visual-motion sensitivity, falls, driving impairment, and recovery time.

Medication review is essential. Potential contributors include antihypertensives, sedatives, antiseizure medications, antidepressants, anticholinergics, cannabis, alcohol, aminoglycosides, selected chemotherapy agents, and chronic vestibular suppressants.

The examination should assess spontaneous and gaze-evoked nystagmus, ocular alignment and skew, smooth pursuit when appropriate, head impulse response in the correct clinical context, hearing asymmetry, focal neurologic deficits, cerebellar signs, orthostatic blood pressure, peripheral neuropathy, stance, and gait.

Dix-Hallpike testing is appropriate when brief positional vertigo is described. Supine roll testing should be considered when the history suggests horizontal-canal BPPV. Audiometry is appropriate when tinnitus, aural fullness, hearing fluctuation, or hearing asymmetry is present.

HINTS and imaging

The HINTS examination is intended for patients with an acute vestibular syndrome, generally including acute persistent vertigo and spontaneous nystagmus, and should be performed by clinicians trained in its use. It should not be used as a generic stroke screen in patients with intermittent dizziness, no nystagmus, or a different vestibular syndrome.

For acute vestibular syndrome, GRACE-3 recommends against routine CT and against routine first-line MRI when a clinician trained in HINTS is available. MRI is recommended as a confirmatory test after a central or equivocal HINTS examination. For spontaneous episodic vestibular syndrome, vascular imaging is considered when TIA is a concern. For triggered episodic vestibular syndrome, routine CT or MRI is discouraged when typical BPPV is identified, unless atypical features are present.

In ambulatory practice, neuroimaging becomes more appropriate when there are focal neurologic findings, central ocular motor abnormalities, severe new headache, progressive neurologic symptoms, substantial vascular risk, new late-life onset, an atypical or changing pattern, cancer, immunosuppression, or asymmetric sensorineural hearing loss requiring internal auditory canal or posterior fossa assessment.

Therapeutic Considerations

Treatment should be individualized according to attack frequency, disability, falls, emergency-department use, comorbid migraine headache, pregnancy potential, cardiovascular status, psychiatric comorbidity, sleep quality, cognitive vulnerability, and coexisting vestibular diagnoses.

Most pharmacologic treatment is extrapolated from migraine-headache management or supported by small vestibular migraine studies. No therapy should be presented as definitively curative or disease-modifying for vestibular migraine. The aim is to reduce attack burden, improve function, manage coexisting migraine, and address persistent imbalance or visual-motion intolerance while limiting treatment-related harm.

An individualized preventive trial may be considered when attacks are frequent, prolonged, disabling, associated with falls or emergency care, or accompanied by a substantial migraine burden. The diagnosis and treatment response should be reassessed at predefined intervals.

Acute Treatment

The evidence supporting acute pharmacologic treatment of vestibular migraine remains very sparse. A 2023 Cochrane review identified only two controlled studies, both evaluating triptans. All effect estimates were rated very low certainty, and the review could not determine whether triptans improve vestibular migraine symptoms.

Triptans

A triptan may be considered for a concurrent typical migraine headache when clinically appropriate. It should not be represented as a proven vestibular abortive.

Before prescribing, clinicians should review the selected product’s complete contraindications, cardiovascular risk-assessment requirements, drug interactions, and organ-function restrictions. Sumatriptan labeling includes contraindications involving ischemic or vasospastic coronary disease, prior stroke or TIA, peripheral vascular disease, ischemic bowel disease, uncontrolled hypertension, accessory-pathway arrhythmias, recent use of another triptan or ergot derivative, MAO-A inhibitor use, serious hypersensitivity, and severe hepatic impairment. Cardiovascular evaluation is recommended for triptan-naive patients with multiple cardiovascular risk factors.

Vestibular suppressants and antiemetics

Vestibular suppressants and antiemetics may be considered for short-term severe vertigo or nausea. Chronic or frequent use can produce sedation, increase fall and driving risk, complicate clinical assessment, and potentially interfere with vestibular compensation.

Current meclizine labeling warns about drowsiness and driving impairment, additive CNS depression with alcohol or other CNS depressants, anticholinergic effects, and caution in patients with asthma, glaucoma, or prostatic enlargement. Potential CYP2D6 interactions should also be reviewed.

Gepants and ditans

Gepants and ditans are migraine therapies rather than established vestibular migraine-specific treatments. Rimegepant is approved for acute migraine treatment and preventive treatment of episodic migraine in adults, not specifically for vestibular migraine.

Current rimegepant labeling contraindicates use in patients with a history of serious hypersensitivity to rimegepant or its components. Serious reactions can be delayed. The label also warns about new or worsening hypertension and Raynaud phenomenon. Strong CYP3A inhibitors and strong or moderate CYP3A inducers should be avoided, and dosing separation is required with selected moderate CYP3A or potent P-glycoprotein inhibitors. Use should be avoided in severe hepatic impairment.

Preventive Treatment

The 2023 Cochrane review of pharmacologic prophylaxis included only three small controlled studies and concluded that the evidence was low or very low certainty. Newer reviews have expanded the evidence base, but their conclusions require careful interpretation.

A 2025 systematic review included three randomized trials and six cohort studies. Favorable signals were reported for propranolol, topiramate, CGRP-targeting therapies, and adjunctive vestibular rehabilitation, but substantial heterogeneity prevented meta-analysis. A 2025 network meta-analysis included five randomized trials and found moderate-certainty evidence only for galcanezumab; certainty for most other interventions was low or very low, and the highest propranolol ranking relied heavily on indirect evidence.

These newer analyses support cautious therapeutic trials but do not establish one universally preferred preventive regimen.

Beta blockers

Beta blockers may be considered when a patient’s migraine phenotype coexists with hypertension, tremor, or another appropriate indication. Vestibular migraine-specific evidence remains limited.

The multicenter PROVEMIG trial was terminated early because of poor recruitment and was underpowered to establish efficacy. It did not demonstrate superiority of metoprolol over placebo for vertigo outcomes, but it also could not exclude a clinically meaningful effect. Propranolol was compared with venlafaxine in a randomized study, but the absence of a placebo group limits causal inference.

Contraindications and precautions are agent-specific. Propranolol is contraindicated in cardiogenic shock, sinus bradycardia, greater-than-first-degree heart block, bronchial asthma, and serious hypersensitivity. Blood pressure, heart rate, conduction disease, pulmonary disease, heart-failure status, and the risk of abrupt withdrawal should be reviewed. Stable compensated heart failure should not be converted into a class-wide beta-blocker contraindication.

Topiramate

Topiramate may be considered in selected patients with substantial migraine burden, particularly when its weight effects are clinically acceptable. Vestibular migraine evidence is based mainly on small or non-placebo-controlled studies and extrapolation from migraine prevention.

Current labeling includes warnings for acute angle-closure glaucoma, metabolic acidosis, cognitive and neuropsychiatric effects, suicidality, fetal toxicity, hyperammonemia or encephalopathy, nephrolithiasis, hypohidrosis, and serious hypersensitivity reactions. Serum bicarbonate monitoring, renal-stone risk, cognitive vulnerability, reproductive potential, and interactions with valproate or other carbonic anhydrase inhibitors require attention.

Valproate and divalproex

Divalproex has an FDA indication for migraine prophylaxis but not specifically for vestibular migraine. Its risk profile generally makes it a poor choice for vestibular migraine when safer alternatives are available.

The boxed warning addresses fatal hepatotoxicity, fetal risk, and potentially fatal pancreatitis. For migraine prophylaxis, valproate is contraindicated in pregnant patients and in women of childbearing potential who are not using effective contraception. Other contraindications and precautions include significant hepatic disease, urea-cycle disorders, and selected POLG-related mitochondrial disorders.

Venlafaxine and tricyclic antidepressants

Venlafaxine may be considered when vestibular migraine coexists with depression, anxiety, or a PPPD-like chronic dizziness phenotype. The evidence does not establish it as a vestibular-specific drug.

Blood pressure should be controlled before treatment and monitored regularly. Sustained elevation may require dose reduction or discontinuation. Serotonergic interactions, discontinuation symptoms, hyponatremia, bleeding risk, and activation of mania or hypomania should also be considered.

A tricyclic antidepressant may be considered when insomnia, chronic pain, or migraine headache coexists. Anticholinergic effects, sedation, orthostatic symptoms, cardiac conduction effects, urinary retention, constipation, glaucoma risk, and falls are important, especially in older adults. Amitriptyline labeling recommends low initial doses and close observation in older patients because of increased sensitivity to anticholinergic and CNS effects.

CGRP-targeting therapies

The American Headache Society considers CGRP-targeting therapies first-line options for migraine prevention generally. That position statement does not establish vestibular migraine as a separately proven indication.

The INVESTMENT study was a single-site, placebo-controlled pilot trial of galcanezumab. Forty participants were randomized and 38 were included in the modified intention-to-treat analysis. Galcanezumab improved several dizziness-related outcomes over 3 months, including the Dizziness Handicap Inventory and monthly definite dizzy days. No serious adverse events were observed. The small sample, short follow-up, single-site design, and inclusion of probable vestibular migraine limit generalizability.

CGRP-targeting products have different indications, administration requirements, interactions, and warnings. Current galcanezumab labeling includes serious hypersensitivity, constipation with serious complications, new or worsening hypertension, and Raynaud phenomenon. Current erenumab labeling contains the same four major warning categories. These postmarketing warnings should be discussed proportionately and should not be generalized to identical incidence or severity across every CGRP-targeting agent.

Table 2. Treatment Options, Evidence, and Major Limitations

Treatment option	Evidence and potential clinical role	Major risks or limitations
Triptan	Very low-certainty evidence for vestibular symptoms; may be considered for a concurrent typical migraine headache	Review complete product-specific vascular, neurologic, hepatic, interaction, and hypersensitivity contraindications
Meclizine or another vestibular suppressant	Short-term symptomatic use for severe vertigo or nausea	Sedation, driving impairment, falls, anticholinergic effects, CNS-depressant interactions, and concern with chronic use
Beta blocker	Limited and mixed vestibular migraine-specific evidence; may fit selected patients with an appropriate comorbidity	Risks and contraindications are agent-specific; review asthma, bradycardia, heart block, blood pressure, heart-failure status, and withdrawal
Topiramate	Small studies and migraine-prevention extrapolation	Cognitive effects, metabolic acidosis, nephrolithiasis, ocular reactions, fetal risk, hyperammonemia, and monitoring burden
Valproate or divalproex	Migraine-prophylaxis indication but limited vestibular migraine evidence	Boxed warnings; contraindicated for migraine prophylaxis in pregnancy and in women of childbearing potential not using effective contraception
Venlafaxine or tricyclic antidepressant	Limited studies and migraine extrapolation; may fit selected psychiatric, sleep, pain, or PPPD overlap	Blood pressure and discontinuation concerns with venlafaxine; anticholinergic, cardiac, cognitive, and fall risks with tricyclics
CGRP-targeting therapy	Small randomized galcanezumab trial and emerging evidence; may be considered for substantial migraine burden or selected refractory cases	Migraine approval does not equal vestibular migraine-specific approval; current product warnings and access limitations must be reviewed
Vestibular rehabilitation	Newer reviews suggest improvement in dizziness-related disability in selected patients	High heterogeneity, variable protocols, substantial observational evidence, and uncertainty about optimal candidates and durability

Nonpharmacologic Management

Sleep regularity, adequate hydration, graded physical activity, avoidance of medication overuse, moderation of excessive alcohol intake, and individualized trigger recognition are reasonable components of migraine care. These interventions should be presented as supportive strategies rather than proven curative treatment for vestibular migraine.

Excessively restrictive elimination diets should be avoided unless a reproducible trigger has been identified or the diet is supervised appropriately. Broad dietary prohibitions may increase burden without clear evidence of benefit.

Vestibular rehabilitation

Vestibular rehabilitation may be considered for persistent imbalance, visual-motion sensitivity, vestibular deconditioning, gait impairment, or coexisting PPPD. Programs may include habituation, gaze stabilization, balance training, substitution strategies, and graded exposure to motion or visually complex environments.

The evidence has evolved since the 2023 Cochrane review, which found low or very low-certainty evidence from small studies. Two 2026 systematic reviews reported improvement in dizziness-related and functional outcomes, including reductions in Dizziness Handicap Inventory scores. However, high heterogeneity, variable rehabilitation protocols, limited blinding, observational designs, and reliance on patient-reported outcomes restrict certainty and generalizability.

Vestibular rehabilitation is therefore reasonable for selected functional impairments, but it should not be described as proven to prevent all vestibular migraine attacks. A multimodal plan may be clinically appropriate, although comparative evidence has not established multimodal treatment as uniformly superior to well-selected individual interventions.

Patient Selection and Risk Stratification

The diagnosis is most coherent when a patient has recurrent qualifying vestibular episodes, a current or previous migraine diagnosis, reproducible migrainous features during at least half of the episodes, and no stronger alternative explanation.

Broader evaluation is particularly important with:

• Progressive unilateral hearing loss
• Persistent focal neurologic deficits
• Central ocular motor findings
• Severe gait ataxia
• Abrupt persistent vertigo
• A new or substantially changed pattern later in life
• Strictly positional attacks with characteristic BPPV findings
• Chronic daily disequilibrium without a clear episodic component
• Significant vascular risk
• Cancer or immunosuppression

Treatment intensity should reflect disability and risk. Rare, self-limited episodes may require education, limited rescue treatment, and follow-up. Frequent or prolonged attacks, falls, emergency visits, inability to drive, or substantial concurrent migraine burden may justify an individualized preventive trial.

A patient with vascular risk factors, central ocular motor abnormalities, severe gait impairment, focal neurologic symptoms, or abrupt persistent vertigo should not be managed as having uncomplicated vestibular migraine until a dangerous central cause has been reasonably evaluated.

Limitations of the Evidence

Vestibular migraine lacks a definitive biomarker. Diagnostic criteria improve consistency but do not eliminate overlap with BPPV, Ménière’s disease, PPPD, vestibular neuritis, anxiety disorders, concussion, cervical pain syndromes, medication-related dizziness, or autonomic disorders.

The treatment literature has expanded but remains limited compared with the broader migraine evidence base. Acute-treatment trials are particularly sparse. Preventive studies use variable diagnostic criteria, small samples, different outcome measures, short follow-up, and heterogeneous interventions. Some newer conclusions depend on observational studies or indirect network comparisons.

Response to a migraine preventive does not prove that the original diagnosis was vestibular migraine. Improvement may reflect treatment of concurrent migraine headache, anxiety, PPPD, sleep disturbance, or another overlapping condition.

These evidence limitations restrict confidence in comparative treatment selection and contribute to practice variation and reliance on extrapolation from migraine-headache management. They should not be interpreted as proof that all available treatments are ineffective.

Future Directions

Future trials should use contemporary diagnostic criteria, distinguish definite from probable vestibular migraine, and stratify participants by episodic versus persistent interictal symptoms. Multicenter placebo-controlled studies should use harmonized vestibular and headache outcomes, including attack frequency, definite dizzy days, dizziness-related disability, falls, driving safety, functional participation, and adverse events.

Head-to-head comparative studies are needed for established migraine preventives, CGRP-targeting therapies, and rehabilitation strategies. Longer follow-up is necessary to assess durability, discontinuation effects, and delayed safety outcomes.

Research should also clarify the relationship among vestibular migraine, PPPD, Ménière’s disease, and persistent interictal vestibular symptoms. Preliminary descriptions of a chronic vestibular migraine phenotype are clinically useful for hypothesis generation but require consensus validation before being treated as formal diagnostic criteria.

References

Almohammed, H. A., Thalib, H. I., Kushara, K. F., et al. (2025). Prophylactic management of vestibular migraine: A systematic review. Annals of Clinical and Translational Neurology, 12(12), 2384-2397.https://doi.org/10.1002/acn3.70234. PMID: 41166161.

Bárány Society. (2022). International Classification of Vestibular Disorders consensus documents. Retrieved July 27, 2026.

Basura, G. J., Adams, M. E., Monfared, A., et al. (2020). Clinical practice guideline: Ménière’s disease. Otolaryngology-Head and Neck Surgery, 162(2 Suppl), S1-S55. https://doi.org/10.1177/0194599820909438. PMID: 32267799.

Bayer, O., Adrion, C., Al Tawil, A., Mansmann, U., Strupp, M., & PROVEMIG Investigators. (2019). Results and lessons learned from a randomized controlled trial: Prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials, 20, 813. https://doi.org/10.1186/s13063-019-3903-5. PMID: 31888723.

Bhattacharyya, N., Gubbels, S. P., Schwartz, S. R., et al. (2017). Clinical practice guideline: Benign paroxysmal positional vertigo (update). Otolaryngology-Head and Neck Surgery, 156(3 Suppl), S1-S47. https://doi.org/10.1177/0194599816689667. PMID: 28248609.

Charles, A. C., Digre, K. B., Goadsby, P. J., Robbins, M. S., Hershey, A., & American Headache Society. (2024). Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. Headache, 64(4), 333-341.  https://doi.org/10.1111/head.14692. PMID: 38466028.

DailyMed. (2026a).  AIMOVIG (erenumab-aooe) injection: Prescribing information. U.S. National Library of Medicine. Retrieved July 27, 2026.

DailyMed. (2026b). Amitriptyline hydrochloride tablet: Prescribing information. U.S. National Library of Medicine. Retrieved July 27, 2026.

DailyMed. (2026c). Divalproex sodium delayed-release tablet: Prescribing information. U.S. National Library of Medicine. Retrieved July 27, 2026.

DailyMed. (2026d). EMGALITY (galcanezumab-gnlm) injection: Prescribing information. U.S. National Library of Medicine. Retrieved July 27, 2026.

DailyMed. (2026e). Meclizine hydrochloride tablet: Prescribing information. U.S. National Library of Medicine. Retrieved July 27, 2026.

DailyMed. (2026f). NURTEC ODT (rimegepant sulfate): Prescribing information. U.S. National Library of Medicine. Retrieved July 27, 2026.

DailyMed. (2026g). Propranolol hydrochloride tablet: Prescribing information. U.S. National Library of Medicine. Retrieved July 27, 2026.

DailyMed. (2026h). Sumatriptan succinate tablet: Prescribing information. U.S. National Library of Medicine. Retrieved July 27, 2026.

DailyMed. (2026i). Topiramate tablet: Prescribing information. U.S. National Library of Medicine. Retrieved July 27, 2026.

DailyMed. (2026j). Venlafaxine hydrochloride tablet: Prescribing information. U.S. National Library of Medicine. Retrieved July 27, 2026.

Edlow, J. A., Carpenter, C., Akhter, M., et al. (2023). Guidelines for reasonable and appropriate care in the emergency department 3 (GRACE-3): Acute dizziness and vertigo in the emergency department. Academic Emergency Medicine, 30(5), 442-486. https://doi.org/10.1111/acem.14728. PMID: 37166022.

El Ahdab, J., Vilardo, M., Ong, B., et al. (2026). The effect of vestibular rehabilitation in the management of vestibular migraine in adults: A systematic review and meta-analysis. Headache, 66(1), 77-87. https://doi.org/10.1111/head.70002.

Formeister, E. J., Rizk, H. G., Kohn, M. A., & Sharon, J. D. (2018). The epidemiology of vestibular migraine: A population-based survey study. Otology & Neurotology, 39(8), 1037-1044.  https://doi.org/10.1097/MAO.0000000000001900. PMID: 30020261.

Headache Classification Committee of the International Headache Society. (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38(1), 1-211.  https://doi.org/10.1177/0333102417738202.

International Headache Society. (2026). A1.6.6 Vestibular migraine. ICHD-3 online. Retrieved July 27, 2026.

Lempert, T., Olesen, J., Furman, J., et al. (2022). Vestibular migraine: Diagnostic criteria update. Journal of Vestibular Research, 32(1), 1-6. https://doi.org/10.3233/VES-201644. PMID: 34719447.

Rust, H. M., & Palla, A. (2026). The interictal symptom burden in vestibular migraine: A condition in need of recognition. Frontiers in Neurology, 17, 1800235.

https://doi.org/10.3389/fneur.2026.1800235. PMID: 42164128.

Salviz, M., Yuce, T., Acar, H., Karatas, A., & Acikalin, R. M. (2016). Propranolol and venlafaxine for vestibular migraine prophylaxis: A randomized controlled trial. The Laryngoscope, 126(1), 169-174.  https://doi.org/10.1002/lary.25445. PMID: 26228645.

Sharon, J. D., Krauter, R., Chae, R., et al. (2024). A placebo-controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study. Headache, 64(10), 1264-1272.  https://doi.org/10.1111/head.14835. PMID: 39344988.

Sfakianaki, I., Nikitas, C., & Kikidis, D. (2026). The effectiveness of vestibular rehabilitation in vestibular migraine: A systematic review. Journal of the Association for Research in Otolaryngology, 27(2), 137-166.  https://doi.org/10.1007/s10162-026-01042-2. PMID: 41840297.

Smyth, D., Britton, Z., Murdin, L., Arshad, Q., & Kaski, D. (2022). Vestibular migraine treatment: A comprehensive practical review. Brain, 145(11), 3741-3754.  https://doi.org/10.1093/brain/awac264. PMID: 35859353.

Staab, J. P., Eckhardt-Henn, A., Horii, A., et al. (2017). Diagnostic criteria for persistent postural-perceptual dizziness (PPPD): Consensus document of the Committee for the Classification of Vestibular Disorders of the Bárány Society. Journal of Vestibular Research, 27(4), 191-208.  https://doi.org/10.3233/VES-170622. PMID: 29036855.

Vasireddy, S., Biswas, S., Kollu, R., et al. (2025). Comparative effectiveness and safety of preventive treatments for vestibular migraine: A systematic review and network meta-analysis. BMC Neurology, 25(1), 513. https://doi.org/10.1186/s12883-025-04490-0. PMID: 41469852.

Villar-Martinez, M. D., & Goadsby, P. J. (2024). Vestibular migraine: An update. Current Opinion in Neurology, 37(3), 252-263. https://doi.org/10.1097/WCO.0000000000001257. PMID: 38619053.

Webster, K. E., Dor, A., Galbraith, K., et al. (2023a). Pharmacological interventions for acute attacks of vestibular migraine. Cochrane Database of Systematic Reviews, 2023(4), CD015322.  https://doi.org/10.1002/14651858.CD015322.pub2. PMID: 37042545.

Webster, K. E., Dor, A., Galbraith, K., et al. (2023b). Pharmacological interventions for prophylaxis of vestibular migraine. Cochrane Database of Systematic Reviews, 2023(4), CD015187. https://doi.org/10.1002/14651858.CD015187.pub2. PMID: 37073858.

Webster, K. E., Dor, A., Galbraith, K., et al. (2023c). Non-pharmacological interventions for prophylaxis of vestibular migraine. Cochrane Database of Systematic Reviews, 2023(4), CD015321. https://doi.org/10.1002/14651858.CD015321.pub2. PMID: 37042522.